IGF1R and breast neoplasm: Preclinical studies have shown that several dual IGF-1R/IR RTKi, including OSI-906 (linsitinib) [159], BMS-554417 [148], and BMS-754807 [160,161], exhibit anti-proliferative and pro-apoptotic affects in breast tumor cells, and inhibit breast tumor growth in vivo when given alone or in combination with hormone therapy.